Page 39 - MBCA_FULL REPORT_FINAL_FOR_WEB

Table 2: Trial Phase and Number of Drugs Studied in the 224 MBC Clinical Trials

Trial Category No. of Trials No. of Drugs No. of No. of No. of No. of
under Study* Phase I Phase Phase II Phase
I/II III

Targeted Trials Assigned to Hallmark of
Cancer Category (n=162)
1. Sustaining Proliferative Signaling
(n=95)
Total 95 69 41 7 38 9
PI3/Akt/mTOR 37 26 17 4 13 3
JAK 2 1 0 1 1 0
Notch 3 2 3 0 0 0
RAF/MEK/ERK/ALK 4 4 2 0 2 0
IGF 1 1 0 1 0 0
ERB receptors 29 20 11 0 13 5
Hormone-mediated 13 10 6 0 6 1
PTEN Mutation 1 1 1 0 0 0
Other 5 4 1 1 3 0
2. Evading Growth Suppressors (n=9)
Cyclin-Dependent Kinase Inhibitors 9 3 3 2 1 3
3. Inducing Angiogenesis (n=4)
VEGF Signaling Inhibitors 4 4 3 0 0 1
4. Resisting Cell Death (n=1)
IAP (Inhibit apoptosis proteins) 1 1 1 0 0 0
5. Enabling Replicative Immortality
(n=0)
Telomerase Inhibitors 0 0 0 0 0 0
6. Genome Instability and Mutation
(n=25)
Total 25 10 11 6 4 4
PARP Inhibitors 16 5 8 3 3 2
HDAC Inhibitors 8 4 3 3 0 2
Other 1 1 0 0 1 0

Table continued next page

39